A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT05835011 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Termination due to discontinuation of magrolimab development in MDS.

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Decitabine/Cedazuridine
DRUG: Magrolimab

Sponsor

Astex Pharmaceuticals, Inc.